The World Health Organization (WHO) is recommending a twice-yearly injection of lenacapavir for prevention of HIV, according ...

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...

Findings from Kenya by CEMA at the International AIDS Society Conference on HIV ScienceRwanda, July 15, 2025-- The University of Nairobi, Center for Epidemiological Modelling and Analysis (CEMA), has ...

Despite the recent approval of lenacapavir as a twice yearly PrEP, there is still a need for choice in HIV prevention, argue ...

The World Health Organization (WHO) chief on Monday called on world leaders to prioritize HIV prevention and embrace ...

A larger role for China, perhaps, and the fraught issue of integrating HIV services into services for other diseases.

HIV pharma leaders are at Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

Conference on HIV Science officially opened Monday in the Rwandan capital of Kigali, with a strong call to accelerate access to long-acting HIV prevention and treatment innovations amid growing global ...

Rahway, New Jersey Wednesday, July 16, 2025, 17:30 Hrs [IST] ...

LEN is the first long-acting PrEP product that requires only two injections per year, offering an appealing alternative to ...

Scientists, researchers, policy makers and HIV/AIDS advocates at a meeting in Kigali, Rwanda, from July 13-17 for the 13th International AIDS Conference on HIV Science (IAS 2025), have raised an alarm ...